The first generic version of Keveyis® (dichlorphenamide) tablets has been made available by Torrent Pharma.
Dichlorphenamide is a carbonic anhydrase inhibitor approved for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. Primary periodic paralysis is a rare hereditary condition characterized by episodic attacks that affect the muscles resulting in muscle weakness or temporary paralysis.
Keveyis was the first drug approved by the FDA for this condition in 2015. The approval was based on data from 2 trials that showed treatment with dichlorphenamide resulted in fewer attacks of muscle weakness in both patients with hyperkalemic and hypokalemic periodic paralysis.
Torrent’s dichlorphenamide tablets are supplied as 50mg tablets in 30- and 100-count bottles. The Company is distributing the product through select specialty pharmacies.
- Torrent Pharma launches first and only generic version of Keveyis® (dichlorphenamide) tablets in the United States. News release. Torrent Pharma. Accessed April 6, 2023. https://www.prnewswire.com/news-releases/torrent-pharma-launches-first-and-only-generic-version-of-keveyis–dichlorphenamide-tablets-in-the-united-states-301791919.html.